Abstract
Kenneth A. Jacobson, Zhan‐Guo Gao, Silvia Paoletta, Evgeny Kiselev, Saibal Chakraborty, P. Suresh Jayasekara, Ramachandran Balasubramanian, Dilip K. Tosh
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Preface: special issue on medicinal chemistry of purines
10.1007/s11302-008-9120-4 · 2009
10.1007/978-1-60761-274-2_3
10.1007/978-1-60761-274-2_3 · 2009
Introduction and perspective, historical note
10.3389/fncel.2013.00227 · 2013
10.1007/s11302-012-9309-4
10.1007/s11302-012-9309-4
10.1111/j.1476-5381.2009.00337.x
10.1111/j.1476-5381.2009.00337.x
10.1126/science.1164772
10.1126/science.1164772
10.1126/science.1202793
10.1126/science.1202793
10.1038/nature13083
10.1038/nature13083
10.1038/nature13288
10.1038/nature13288
10.1038/nature08198
10.1038/nature08198
Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design
10.1021/jm201376w · 2012
10.1021/jm901647p
10.1021/jm901647p
10.1021/jm100240h
10.1021/jm100240h
High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks
10.1186/2193-9616-1-23 · 2013
10.1021/ci300615u
10.1021/ci300615u
10.1021/jm300095s
10.1021/jm300095s
Structure–activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors
1993
John W. Daly and the early characterization of adenosine receptors
10.3987/com-08-s(d)memoire-2 · 2009
8-Aryl- and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors
10.1021/jm00398a020 · 1988
10.1371/journal.pone.0097858
10.1371/journal.pone.0097858
A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure–activity relationship analysis and binding requirements of agonists and antagonists
10.2174/138161208784480081 · 2008
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities
10.1007/s00210-003-0749-9 · 2003
New substituted 9-alkylpurines as adenosine receptor ligands
10.1016/s0968-0896(98)00007-8 · 1998
N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor
10.1021/jm00113a029 · 1991
10.1016/j.str.2011.06.014
10.1016/j.str.2011.06.014
Integrated methods for the construction of three-dimensional models of structure–function relations in G protein-coupled receptors
10.1016/s1043-9471(05)80049-7 · 1995
10.1021/jm300396n
10.1021/jm300396n
10.1021/jm4007966
10.1021/jm4007966
10.1021/ml100008s
10.1021/ml100008s
10.1038/nature10361
10.1038/nature10361
Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches
10.1039/c2md20348k · 2013
10.1021/jm801456g
10.1021/jm801456g
10.1021/jm960306
10.1021/jm960306
10.1016/j.bbrc.2013.06.040
10.1016/j.bbrc.2013.06.040
The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure
10.1080/02713680590953147 · 2005
10.1016/j.bcp.2013.01.021
10.1016/j.bcp.2013.01.021
10.1007/s11302-012-9303-x
10.1007/s11302-012-9303-x
10.1038/nature11701
10.1038/nature11701
Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor
10.1016/j.ejmech.2013.04.007 · 2013
10.1124/mol.112.082198
10.1124/mol.112.082198
10.1016/j.nucmedbio.2008.10.003
10.1016/j.nucmedbio.2008.10.003 · doi-reference
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists
10.1021/jm9905965 · doi-reference
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4 and P2Y11, but not P2Y6 receptors
10.1021/jm010369e · doi-reference
10.1016/j.bmc.2004.02.037
10.1016/j.bmc.2004.02.037 · doi-reference
Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes
10.1021/cb500614p · doi-reference
The role of P2Y14 and other P2Y receptors in degranulation of human LAD2 mast cells
10.1007/s11302-012-9325-4 · doi-reference
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor
10.1124/mol.109.058578 · doi-reference
The P2Y6 receptor stimulates bone resorption by osteoclasts
10.1210/en.2011-1073 · doi-reference
Potent P2Y6 receptor mediated contractions in human cerebral arteries
10.1186/1471-2210-3-4 · doi-reference
10.1164/rccm.201011-1762oc
10.1164/rccm.201011-1762oc · doi-reference
10.1172/jci41541
10.1172/jci41541 · doi-reference
Uridine diphosphate (UDP) stimulates insulin secretion by activation of P2Y6 receptors
10.1016/j.bbrc.2008.03.119 · doi-reference
AMP-activated protein kinase as regulator of P2Y6 receptor-induced secretion in MIN6 mouse pancreatic β cells
10.1016/j.bcp.2012.11.029 · doi-reference
5-OMe-uridine-5′-O-(α-boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y6 receptor protects against death-receptor mediated glial apoptosis
10.1016/j.neulet.2014.06.030 · doi-reference
P2Y1 receptor antagonists as novel antithrombotic agents
10.1016/j.bmcl.2008.04.028 · doi-reference
Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists
10.1021/jm301708u · doi-reference
Inhibition of UDP-glucose-promoted chemotaxis of human neutrophils by a selective high affinity antagonist of the P2Y14 receptor
10.1124/mol.113.085654 · doi-reference
The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14
10.1016/j.bmcl.2011.03.081 · doi-reference
4-Alkyloxyimino derivatives of uridine-5′-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4 and P2Y6 receptors
10.1021/jm500367e · doi-reference
4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y6 receptor
10.1039/c3md00132f · doi-reference
Controlling murine and rat chronic pain through A3 adenosine receptor activation
10.1096/fj.11-201541 · doi-reference
10.1016/j.bcp.2011.06.017
10.1016/j.bcp.2011.06.017 · doi-reference
10.1016/j.bbamem.2010.09.020
10.1016/j.bbamem.2010.09.020 · doi-reference
Pharmacological and therapeutic effects of A3 adenosine receptor (A3AR) agonists
10.1016/j.drudis.2011.10.007 · doi-reference
Medicinal chemistry of A3 adenosine receptor modulators: pharmacological activities and therapeutic implications
10.1021/jm300087j · doi-reference
Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes
10.1016/j.vetimm.2007.08.011 · doi-reference
N-substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects
10.1021/jm960682u · doi-reference
N 6-substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors
10.1016/s0006-2952(03)00153-9 · doi-reference
10.1021/jm300965a
10.1021/jm300965a · doi-reference
10.1002/wmts.68
10.1002/wmts.68 · doi-reference
10.1016/j.bmcl.2014.07.009
10.1016/j.bmcl.2014.07.009 · doi-reference